Lucia Biasutto
Overview
Explore the profile of Lucia Biasutto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benetollo A, Parrasia S, Scano M, Biasutto L, Rossa A, Nogara L, et al.
Biochem Pharmacol
. 2025 Jan;
233:116779.
PMID: 39864467
Sarcoglycanopathies are rare forms of severe muscular dystrophies currently without a therapy. Mutations in sarcoglycan (SG) genes cause the reduction or absence of the SG-complex, a tetramer located in the...
2.
Zoratti M, Biasutto L, Parrasia S, Szabo I
Expert Opin Ther Targets
. 2024 Jan;
28(1-2):1-3.
PMID: 38235549
No abstract available.
3.
Parrasia S, Rossa A, Roncaglia N, Mattarei A, Honisch C, Szabo I, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242749
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and is among the most aggressive and still incurable cancers. Innovative and successful therapeutic strategies are extremely needed....
4.
Bachmann M, Rossa A, Varanita T, Fioretti B, Biasutto L, Milenkovic S, et al.
Cell Death Dis
. 2022 Dec;
13(12):1055.
PMID: 36539400
Ion channels are non-conventional, druggable oncological targets. The intermediate-conductance calcium-dependent potassium channel (K3.1) is highly expressed in the plasma membrane and in the inner mitochondrial membrane (mitoK3.1) of various cancer...
5.
Parrasia S, Szabo I, Zoratti M, Biasutto L
Mol Pharm
. 2022 Sep;
19(11):3700-3729.
PMID: 36174227
Central nervous system (CNS) diseases are among the most difficult to treat, mainly because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach...
6.
La Spina M, Azzolini M, Salmaso A, Parrasia S, Galletta E, Schiavone M, et al.
Oxid Med Cell Longev
. 2022 Jan;
2021:7658501.
PMID: 34992716
Pterostilbene (Pt) is a potentially beneficial plant phenol. In contrast to many other natural compounds (including the more celebrated resveratrol), Pt concentrations producing significant effects can also be reached with...
7.
Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler K, Romio M, Rigoni G, et al.
Redox Biol
. 2021 Jul;
45:102036.
PMID: 34210643
No abstract available.
8.
Biasutto L, Mattarei A, Paradisi C
Methods Mol Biol
. 2021 Jun;
2275:141-160.
PMID: 34118036
Resveratrol and quercetin are among the most studied plant polyphenols, and have many health-promoting actions. Strategies to accumulate them into mitochondria may be of therapeutic relevance, since these compounds are...
9.
Peruzzo R, Corra S, Costa R, Brischigliaro M, Varanita T, Biasutto L, et al.
Nat Commun
. 2021 Apr;
12(1):2103.
PMID: 33833234
Mitochondrial diseases impair oxidative phosphorylation and ATP production, while effective treatment is still lacking. Defective complex III is associated with a highly variable clinical spectrum. We show that pyocyanin, a...
10.
Parrasia S, Rossa A, Varanita T, Checchetto V, De Lorenzi R, Zoratti M, et al.
Pharmaceuticals (Basel)
. 2021 Feb;
14(2).
PMID: 33562146
A developing family of chemotherapeutics-derived from 5-(4-phenoxybutoxy)psoralen (PAP-1)-target mitochondrial potassium channel mtKv1.3 to selectively induce oxidative stress and death of diseased cells. The key to their effectiveness is the presence...